BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17287406)

  • 1. Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease.
    Abraham-Nordling M; Wallin G; Lundell G; Törring O
    Eur J Endocrinol; 2007 Feb; 156(2):173-9. PubMed ID: 17287406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.
    Abraham-Nordling M; Törring O; Hamberger B; Lundell G; Tallstedt L; Calissendorff J; Wallin G
    Thyroid; 2005 Nov; 15(11):1279-86. PubMed ID: 16356093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graves' Disease: Can It Be Cured?
    Wiersinga WM
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):29-38. PubMed ID: 30912336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
    Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
    Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
    [No Abstract]   [Full Text] [Related]  

  • 6. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
    Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
    Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
    Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
    J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
    Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
    Gamstedt A; Karlsson A
    J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
    Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graves' disease: diagnostic and therapeutic challenges (multimedia activity).
    Kahaly GJ; Grebe SK; Lupo MA; McDonald N; Sipos JA
    Am J Med; 2011 Jun; 124(6):S2-3. PubMed ID: 21605717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study.
    Pearce SHS; Dayan C; Wraith DC; Barrell K; Olive N; Jansson L; Walker-Smith T; Carnegie C; Martin KF; Boelaert K; Gilbert J; Higham CE; Muller I; Murray RD; Perros P; Razvi S; Vaidya B; Wernig F; Kahaly GJ
    Thyroid; 2019 Jul; 29(7):1003-1011. PubMed ID: 31194638
    [No Abstract]   [Full Text] [Related]  

  • 19. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and clinical relevance of circulating CD4+CD28- T cells in Graves' disease.
    Wang F; Chen L; Shen Q; Liu T; Jiang L; Gu X; Chen L; Sun J; Liu C
    Immunol Lett; 2015 May; 165(1):47-51. PubMed ID: 25839128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.